New Haven, United States
Invivyd is a pioneering player in the biotechnology sector, founded in 2020 and headquartered in the United States. The company specializes in developing monoclonal antibodies that can address evolving viruses more effectively than the human immune system. Its proprietary technology platform sets it apart, capable of monitoring and adapting drug formulations to deliver best-in-class antibodies.
A notable milestone was achieved in March 2024 when Invivyd received emergency use authorization from the U.S. FDA for one of its monoclonal antibody candidates, underlining its capability in addressing urgent health concerns, such as COVID-19.
The company operates within the Biotechnology, Health and Wellness, and Pharmaceutical industries, and most recently raised capital through a Post IPO Equity investment on 01 November 2025. Investors should consider Invivyd's robust technology platform, recent regulatory achievements, and its potential to meet the growing demand for adaptive and high-efficacy treatments.
Genotic